Trials / Completed
CompletedNCT01018264
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- University of South Florida · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | solifenacin succinate (VESIcare) | up to 10mg every day orally |
| DRUG | placebo | placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2009-11-23
- Last updated
- 2021-11-09
- Results posted
- 2015-05-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01018264. Inclusion in this directory is not an endorsement.